Photys Therapeutics and Polymed Begin Phase 1 Trial of PHT-776
WALTHAM, Massachusetts, and HANGZHOU, China, August 13, 2026 Photys Therapeutics, Inc. and Polymed Biopharmaceuticals, Inc. announced the initiation of...
Psoriasis
Advertisement
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Philips Reports Strong Q2 2026 Growth and AI Innovation
Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
NextCure and Avere Strengthen Oral IL-23 Development
SAN FRANCISCO, July 14, 2026 NextCure and privately held Avere Therapeutics have entered into a definitive all-stock merger agreement...
Advertisements
Can-Fite Completes Phase 3 Psoriasis Trial Enrollment
RAMAT GAN, Israel, July 6, 2026 Can-Fite BioPharma announced the completion of enrollment of the first 247 patients in...
LabGenius and LG Chem Partner on AI-Designed Cancer Antibodies
LONDON, United Kingdom, June 18, 2026 LabGenius Therapeutics and LG Chem have entered into a multi-year research collaboration, option,...
Samsung Bioepis and Organon Expand PYZCHIVA Rights in Canada
INCHEON, South Korea & KIRKLAND, Quebec, Canada, June 18, 2026 Samsung Bioepis and Organon have expanded their long-standing biosimilar...
FibroBiologics Reports Durable Psoriasis Immunomodulation Data at SID 2026
HOUSTON, May 22, 2026 FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation...
LEO Pharma Wins China Approval for Enstilar Psoriasis Drug
BALLERUP, Denmark, April 17, 2026 LEO Pharma A/S has secured a major regulatory milestone with the approval of Enstilar®...
Advertisement
